First AD

Second AD

1L treatment of lower-risk MDS beyond luspatercept

For patients who are not suitable to receive 1L luspatercept for LR-MDS, what alternate treatment options would you consider?

What other trials on the horizon are you excited for in the 1L treatment of lower-risk MDS?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 

Peer Exchange

Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy. 

1L treatment of lower-risk MDS beyond luspatercept 

Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification 